Acerca de

Boston, MA – Anodyne is pleased to present preclinical data on our once-weekly GLP-1 patch at the 14th annual Partnerships in Drug Delivery (PODD2024) Conference, held October 28-29 in Boston, MA. 

 

Jake Lombardo, Co-founder & CEO, will be presenting the key results from the development of Anodyne’s GLP-1 patch, where the company's proprietary HeroPatch technology exceeded the delivery of commercial injections. His presentation will cover breakthroughs in transdermal delivery, specifically Anodyne’s solutions to dosage and manufacturing challenges faced by the industry. Evidence of safety and efficacy across preclinical and clinical evaluations will also be covered.

 

Anodyne is developing a once-weekly GLP-1 patch with the potential to reduce side effects and eliminate cold-chain distribution. The preclinical results demonstrated that the patch can achieve multi-milligram delivery, exceeding the delivery of commercial semaglutide injections.

 

Our team, Jake Lombardo, Konstantinos Tzortzakis, and Michael Elliott will be available at Booth 113 to discuss Anodyne’s proprietary HeroPatch™ technology, designed to deliver transdermally multi-milligram doses of large molecules.

 

To get in touch with the Anodyne team, contact us at partnering@theheropatch.com